Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 4
2000 4
2001 4
2002 1
2005 1
2009 1
2012 1
2013 1
2014 1
2015 1
2017 4
2018 1
2020 3
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer.
Jahid S, Ortega JA, Vuong LM, Acquistapace IM, Hachey SJ, Flesher JL, La Serra MA, Brindani N, La Sala G, Manigrasso J, Arencibia JM, Bertozzi SM, Summa M, Bertorelli R, Armirotti A, Jin R, Liu Z, Chen CF, Edwards R, Hughes CCW, De Vivo M, Ganesan AK. Jahid S, et al. Among authors: arencibia jm. Cell Rep. 2022 Apr 5;39(1):110641. doi: 10.1016/j.celrep.2022.110641. Cell Rep. 2022. PMID: 35385746 Free PMC article.
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer.
Jahid S, Ortega JA, Vuong LM, Acquistapace IM, Hachey SJ, Flesher JL, La Serra MA, Brindani N, La Sala G, Manigrasso J, Arencibia JM, Bertozzi SM, Summa M, Bertorelli R, Armirotti A, Jin R, Liu Z, Chen CF, Edwards R, Hughes CCW, De Vivo M, Ganesan AK. Jahid S, et al. Among authors: arencibia jm. Cell Rep. 2022 Apr 26;39(4):110760. doi: 10.1016/j.celrep.2022.110760. Cell Rep. 2022. PMID: 35476990 Free PMC article. No abstract available.
Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β.
Ortega JA, Arencibia JM, Minniti E, Byl JAW, Franco-Ulloa S, Borgogno M, Genna V, Summa M, Bertozzi SM, Bertorelli R, Armirotti A, Minarini A, Sissi C, Osheroff N, De Vivo M. Ortega JA, et al. Among authors: arencibia jm. J Med Chem. 2020 Nov 12;63(21):12873-12886. doi: 10.1021/acs.jmedchem.0c00774. Epub 2020 Oct 20. J Med Chem. 2020. PMID: 33079544 Free PMC article.
Design, Synthesis, Dynamic Docking, Biochemical Characterization, and in Vivo Pharmacokinetics Studies of Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
Arencibia JM, Brindani N, Franco-Ulloa S, Nigro M, Kuriappan JA, Ottonello G, Bertozzi SM, Summa M, Girotto S, Bertorelli R, Armirotti A, De Vivo M. Arencibia JM, et al. J Med Chem. 2020 Apr 9;63(7):3508-3521. doi: 10.1021/acs.jmedchem.9b01760. Epub 2020 Mar 30. J Med Chem. 2020. PMID: 32196342 Free PMC article.
Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer.
Catanzaro E, Betari N, Arencibia JM, Montanari S, Sissi C, De Simone A, Vassura I, Santini A, Andrisano V, Tumiatti V, De Vivo M, Krysko DV, Rocchi MBL, Fimognari C, Milelli A. Catanzaro E, et al. Among authors: arencibia jm. Eur J Med Chem. 2020 Sep 15;202:112504. doi: 10.1016/j.ejmech.2020.112504. Epub 2020 Jul 4. Eur J Med Chem. 2020. PMID: 32712536
Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells.
Ortega JA, Arencibia JM, La Sala G, Borgogno M, Bauer I, Bono L, Braccia C, Armirotti A, Girotto S, Ganesan A, De Vivo M. Ortega JA, et al. Among authors: arencibia jm. J Med Chem. 2017 Jul 13;60(13):5800-5815. doi: 10.1021/acs.jmedchem.7b00472. Epub 2017 Jun 27. J Med Chem. 2017. PMID: 28603987 Free article.
30 results